{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-018619","form_type":"8-K","ticker":"JUNS","cik":"0001679628","company_name":"JUPITER NEUROSCIENCES, INC.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.619590+00:00","generated_at":"2026-05-18T08:46:25.286920+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Jupiter Neurosciences regains Nasdaq minimum bid price compliance","bullets":["Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).","Company had been notified of deficiency on March 21, 2025 with a 180-day cure period ending September 17, 2025.","Nasdaq considers the matter closed; common stock (JUNS) continues listing on Nasdaq Capital Market.","Jupiter is a clinical-stage pharma developing JOTROL resveratrol platform for CNS disorders and longevity products."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-018619","json":"https://secwatch.observer/filing/0001641172-25-018619.json","markdown":"https://secwatch.observer/filing/0001641172-25-018619.md","text":"https://secwatch.observer/filing/0001641172-25-018619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/0001641172-25-018619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:46:25.286920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}